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Ewing's sarcoma (ES) associated with high osyeolytic lesions typically arises in the bones of children and
adolescents. The development of multi-disciplinary therapy has increased current long-term survival rates to
greater than 50% but only 20% for high risk group patients (relapse, metastases, etc.). Among new therapeutic
approaches, osteoprotegerin (OPG), an anti-bone resorption molecule may represent a promising candidate to
inhibit RANKL-mediated osteolytic component of ES and consequently to limit the tumor development.
Xenogenic orthotopic models of Ewing's sarcomawere induced by intra-osseous injection of human TC-71
ES cells. OPG was administered in vivo by non-viral gene transfer using an amphiphilic non ionic block
copolymer. ES bearing mice were assigned to controls (no treatment, synthetic vector alone or F68/empty
pcDNA3.1 plasmid) and hOPG treated groups. A substantial but not signiﬁcant inhibition of tumor
development was observed in the hOPG group as compared to control groups. Marked bone lesions were
revealed by micro-computed tomography analyses in control groups whereas a normal bone micro-
architecture was preserved in the hOPG treated group. RANKL over-expressed in ES animal model was
expressed by tumor cells rather than by host cells. However, TRAIL present in the tumor microenvironment
may interfere with OPG effect on tumor development and bone remodeling via RANKL inhibition.
In conclusion, the use of a xenogenic model of Ewing's sarcoma allowed discriminating between the tumor
and host cells responsible for the elevation of RANKL production observed in this tumor and demonstrated the
relevance of blocking RANKL by OPG as a promising therapy in ES.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ewing's sarcoma (ES) is a high-grade neoplasm representing
the second most common primary bone malignancy in both
children and adults. With a peak incidence at 15 years, this disease
accounts for 2% of childhood cancers [1–3]. ES is deﬁned as a bone
tumor which may occur at any site within the skeleton but
preferentially affects the trunk and the diaphysis of long bones.
Less commonly, it arises in extraskeletal soft tissues (15%). It is
characterized by a rapid tumor growth and extensive bone. This is an open access article und
Médecine, 1 rue Gaston Veil,
fax: +33 240 412860.
. Redini).destruction that can result in bone pain and pathological fracture.
A particularity of ES tumors is the occurrence of a typical
chromosomal translocation that fuses the EWS gene on chromo-
some 22q12 to a member of the ETS transcription gene family,
most commonly to Fli-1 on 11q24 (490% of cases) [4,5]. This
translocation leads to the production of an aberrant transcription
factor that promotes tumorigenicity [6–8]. Due to progress in
surgery and chemotherapy, survival rates have increased from less
than 10% to 55–60% for patients presenting local disease [9].
However, the survival rates decrease to 15–25% when metastases
are detected at diagnosis, or for patient presenting resistance to
treatment or relapsed disease. Moreover, a survival plateau
seems to have been reached with conventional therapies. Accord-
ingly, new therapeutic approaches should be actively explored,
especially for high-risk patients, to increase long-term survival byer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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resistance.
ES is characterized by extensive bone destruction due to
osteolysis. Ewing's sarcoma cells are unable to directly degrade
the bone matrix and accordingly, osteoclast activation and sub-
sequent bone resorption might be responsible for the clinical
features of bone destruction [10]. Indeed, as demonstrated for
bone metastases [11], a vicious cycle between bone cells (osteo-
clasts and osteoblasts) and tumor cells occurs during the devel-
opment of tumor in bone site. Therefore, targeting the osteoclasts
may represent a promising adjuvant strategy for the treatment of
bone tumors. Among the factors involved in the regulation of bone
remodeling, the molecular triad osteoprotegerin (OPG)/receptor
activator of NF-kB (RANK)/RANK Ligand (RANKL) is strongly
implicated [12,13]. Osteoclast differentiation and activation is
mainly mediated by RANKL, a cytokine member of the tumor
necrosis factor (TNF) superfamily (TNFSF11) that binds to its
receptor RANK at the surface of osteoclasts [14]. OPG (TNFRSF11B)
is a soluble protein that acts as a decoy receptor for RANKL
inhibiting osteoclast formation, function and survival by prevent-
ing the binding of RANKL to RANK [15]. Transgenic mice over-
expressing OPG exhibit an osteopetrotic phenotype, whereas OPG-
knockout mice have severe osteoporosis [16,17]. The OPG/RANKL/
RANK system is also involved in various pathologies associated
with tumors in bone [18,19]. Therefore, OPG has demonstrated
increased interest as a therapeutic strategy in malignant bone
pathologies associated with osteolytic lesions [20,21]. Concerning
primary bone tumors, the inhibition of RANKL activity by OPG
induced a signiﬁcant therapeutic effect on bone lesion and tumor
development in two preclinical models of osteosarcoma in mice
(POS-1) and in rats (OSRGa) [22]. This effect was also conﬁrmed by
using the soluble form of the RANKL receptor, RANK-Fc [15] or by
the RNA interference strategy targeting RANKL [23]. In addition,
OPG is also able to bind to the TNF Related Apoptosis Inducing
Ligand (TRAIL), another member of the TNF superfamily (TNFSF10)
[23], thereby limiting its ability to induce apoptosis in tumor cells.
It has been even reported that OPG acts as a pro-tumoral factor in
some cancer cell lines in vitro [24–26]. In addition, Taylor et al.
previously reported that the expression of RANKL in Ewing's
sarcoma cell lines and tissues could support osteoclast activation
[10]. Therefore, targeting this cytokine with OPG may represent a
promising therapeutic option.
The aim of this study was to determine the therapeutic
relevance of blocking RANKL in Ewing's sarcoma by using OPG
administered by non-viral gene transfer approaches in two models
of human Ewing sarcoma in immunodeﬁcient mice. OPG was
administered using amphiphilic polymers constituted by blocks of
poly(ethylene oxide) and of poly(propylene oxide) as previously
reported for osteosarcoma preclinical studies [22]. These synthetic
vectors have been used with high efﬁciency for in vivo gene
transfer in various organs including skeletal and cardiac muscles
[27,28] and in lungs [29]. Intramuscular injections of these
synthetic vectors led to the synthesis of proteins for local beneﬁt
such as dystrophin or of systemic erythropoietin [30].2. Materials and methods
2.1. In vivo experiments
2.1.1. Plasmid constructs
The pcDNA3.1.3-hOPG1-194 contains the cDNA coding for the
truncated form of OPG (1–194) cloned using the pcDNA™
3.3-TOPOs TA clonings Kit (Invitrogen) according to manufac-
turer's recommendations, the empty pcDNA3.1 plasmid (Invitro-
gen) being used as a control.2.1.2. Xenograft models of human Ewing's sarcoma
All procedures involving mice were conducted in accordance
with the institutional guidelines of the French Ethical Committee
(CEEA.PdL.06, protocol number 2010.23). Four-week-old male
athymic mice purchased from Harlan were housed in the Experi-
mental Therapeutic Unit at the Faculty of Medicine of Nantes
(France). The TC-71 ES model was induced by transplantation of a
fragment of tumor (222 mm3) in close contact with the tibia,
resulting from the initial injection of 2106 TC-71 ES cells next to
the tibia. To conﬁrm the effects of OPG, another Ewing's sarcoma
model was developed, induced by i.m. injection of 2106 human
A-673 ES cells in close contact with the tibia, leading to a rapidly
growing tumor in soft tissue with secondary contiguous bone
invasion. Mice were anesthetized by inhalation of a combination of
isoﬂurane/air (1.5%, 1 L/min) and buprenorphine was given by sc
injection during the protocol (0.05 mg/kg; Temgesics, Schering-
Plough).
2.1.3. Synthetic gene transfer
The synthetic vector used in this study (named F68) belongs to
the Lutrol family of vectors, non ionic block copolymers of poly
(ethyleneoxide)75-poly(propyleneoxide)30-poly(ethyleneoxide)75
generously provided by Dr. Bruno Pitard (INSERM UMR1087,
Nantes, France) [30]. Stock solutions were prepared at 6% (w/v)
in water and stored at 4 1C. Formulations of DNA with block
copolymers were prepared by equivolumetric mixing block copo-
lymers in water and DNA solution at the desired concentration
(50 μg/muscle).
2.1.4. Experimental protocol
Groups of 6–8 mice were assigned as control vectors (F68/
pcDNA3.1 alone) and hOPG1-194 (F68/pcDNA3.1-OPG1-194). F68
alone or associated with the empty vector pcDNA3.1 does not
affect tumor development as compared to non-treated mice that
develop the Ewing sarcoma model (data not shown). Mice were
anesthetized by inhalation of a combination of isoﬂurane/air (1.5%,
1 L/min) and the F68/DNA formulations were injected into
both tibial anterior muscles once a week. Because the transgene
expression is optimal seven days after injection of the DNA
formulations, the treatment began 7 days before Ewing's sarcoma
implantation as a preventive treatment, up to 21 days post-
implantation. The truncated form of OPG was chosen in accor-
dance to previous results obtained by our group in osteosarcoma
models, showing that the biological activity of the complete OPG
isoform may be limited by interaction with proteoglycans present
in the extracellular matrix, inhibiting OPG biological availability
[31]. The Ewing sarcoma model was induced by tumor fragment
transplantation or tumor cell injection as described above. The
tumor volume was calculated by using the formula L l2/2, where
L and l are the longest and the smallest perpendicular diameter,
respectively. Treatment continued until each animal showed signs
of morbidity, which included cachexia or respiratory distress, at
which point they were sacriﬁced by cervical dislocation or by CO2
inhalation. The mice were also sacriﬁced for ethical reasons when
the tumor volume exceeded 3000 mm3. Lung tumor dissemination
was assessed at necropsy. The tumor-bearing hind limb was
dissected and kept in 10% paraformaldehyde for radiography,
micro-computed tomography (micro-CT) and histological analyses.
2.1.5. Micro-computed tomography (micro-CT) analysis
Analyses of bone micro-architecture were performed using a
Skyscan 1076 in vivo micro-CT scanner (Skyscan, Kontich,
Belgium). Tests were performed after sacriﬁce on tibias for each
treatment group. All tibias were scanned using the same parameters
(pixel size 18 mm, 50 kV, 0.5-mm Al ﬁlter, 10 min of scanning).
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(Skyscan). The speciﬁc bone volume was quantiﬁed as the relative
Bone volume/total volume measured for each VOI. 3D visualizations
of tibias and heads were realized using ANT software (Skyscan) at
sacriﬁce.2.1.6. In vivo analysis of transgene expression
Blood was drawn intermittently from the retro-orbital vein to
monitor circulating hOPG protein levels throughout the experi-
ment. At necropsy, the tumor tissues were lysed in Reporter Lysis
Buffer (Promega, Madison, USA) supplemented with a protease
inhibitor cocktail (Roche Molecular Biomedicals, Manheim,
Germany), and crushed during 30 s using Ultraturaxs, after which
lysates were centrifuged at 10,000 rpm for 5 min at 4 1C, and
processed for hOPG detection using ELISA kit (R&D Systems)
following the manufacturer's recommendations.2.1.7. RANKL immuno-ﬂuorescence on animal tumor models
After sacriﬁce, tumor samples were ﬁxed in a solution of
paraformaldehyde (PFA) 4% at 4 1C for. The samples were then
cryopreserved consecutively in 6% and 30% sucrose solutions in
PBS pH 7.4 buffer. They were then embedded in Neg50 (Thermo-
Scientiﬁc) and frozen in isopentane cooled to −80 1C. The 40 μm
cryostat sections (also named ﬂoating sections) were then col-
lected in well plates in 1 PBS, 0.1% Thimerosal pH¼7.4 and
stored at 4 1C. Sections were then washed 3 times for 5 min in 1
PBS. Permeabilization is then performed with 1 PBS, 0.1% Triton
100 . The sections were then washed 3 times for 5 min in a
solution of 1 PBS. The unspeciﬁc sites were ﬁrst blocked by
incubating the sections for 25 min in blocking solution 1 [1 PBS
containing 5% goat serum (Dako) and 1% BSA (Sigma)] followed by
endogenous immunoglobulins quenching during 1 h in the block-
ing solution 2 [Fab fragments of goat antibodies directed against
mouse (Jackson Lab) diluted 1/10 in PBS 1 ]. The sections were
then incubated overnight at 4 1C with the primary antibody
targeting human RANKL (R&D) diluted 1/20 in blocking solution
3 [1 PBS containing 5% rabbit serum (Jackson Lab) and 1% BSA].
They are then washed 3 times for 5 min in a 1 PBS and then
incubated for 45 min with the secondary rabbit antibody directed
against goat IgG [Life Technologies] diluted 1/200 in blocking
solution 3. The sections were mounted between slides and cover-
slips using Moviol (Sigma), stored at 4 1C in the dark before being
analyzed by confocal microscopy (imaging platform MicroPicell,
SFR26, Nantes, France).2.1.8. RANKL detection in Ewing's sarcoma experimental model by
species-speciﬁc antibodies
Human or mouse RANKL was analyzed by ELISA on tumor and
muscle lysatesand in serum of mice bearing TC-71 Ewing's sarcoma
tumor. Tumor and muscle fragments were dry frozen and placed in
1 mL RLB 1 (Promega) containing protease cocktail inhibitors
1 (Roche), then ground using a Thurax YellowlineDI 25 Basic
Homogeneizer (IKA). The obtained solution is centrifuged 10 min at
12,000g at 4 1C and the supernatant is kept frozen at −20 1C. Samples
were then analyzed for the production of murine or human RANKL
using ELISA detection kits (R&D systems for mRANKL and Biomedica
for hRANKL).2.1.9. TRAIL detection by ELISA in Ewing's sarcoma
experimental models
hTRAIL production was assessed by ELISA (R&D Systems,
Abingdon, UK) in the supernatant of cultured Ewing sarcoma cells
following the manufacturer's recommendations.2.1.10. RANKL immuno-histochemistry in biopsies of Ewing's
sarcoma patients
Two human biopsies from Ewing's sarcoma patients were
analyzed for RANKL protein expression. Brieﬂy, 3 mm sections
were obtained from decalciﬁed and parafﬁn embedded samples
(from the anatomo-histo-pathology department of Nantes Hospi-
tal). After dewaxing and hydratation, antigen retrieval was per-
formed with proteinase K solution (10 mg/mL in 1 TBS–Tween
0.05%) at 37 1C. Then endogenous peroxydase activity was
quenched with 3% H2O2 and unspeciﬁc sites were blocked with
5% goat serum, 1% BSA in 1 TBS–Tween 0.05% at room tempera-
ture. Primary antibody (monoclonal mouse anti-human RANKL,
R&D) was applied overnight at 4 1C. Immunodetection was per-
formed using Streptavidin–Biotin complex followed by incubation
with DAB Substrate-Chromogen (Dako) and counterstained with
hematoxylin.
2.1.11. TRAIL immuno-histochemistry in biopsies of
Ewing's sarcoma patients
Two human biopsies from Ewing's sarcoma patients were
analyzed for RANKL protein expression. Brieﬂy, 3 mm sections
were obtained from decalciﬁed and parafﬁn embedded samples
(from the anatomo-histo-pathology department of Nantes Hospi-
tal). After dewaxing and hydratation, antigen retrieval was per-
formed with 10 mM citrate buffer at 96 1C for 20 min. Following
steps were performed as described above, except that primary
antibody was goat anti-human TRAIL (R&D).
2.2. In vitro experiments
2.2.1. Ewing sarcoma
Ten human Ewing sarcoma cell lines were used. The A-673, TC-
32, SK-ES-1, and RD-ES cell line were kindly provided by
Dr. S. Burchill (Children's Hospital, Leeds, United Kingdom), the
TC-71, SK-N-MC, STA-ET-1 and EW24 by Dr. O. Delattre (INSERM
UMR830, Paris, France) and the BRZ from Dr. K. Scotlandi (Rizzoli
Institute, Bologna, Italy). The A-673, TC-32 and RD-ES cell lines
were cultured in DMEM (BioWhittaker), and TC-71, SK-ES-1, SK-N-
MC and EW24 cell lines were cultured in RPMI (BioWhittaker)
with 10% fetal bovine serum (FBS; Hyclone). In addition, TC-71 and
STA-ET-1 cells require collagen for adherence and growing: before
cell seeding, ﬂasks were incubated 30 min with 50 mg/mL type I
collagen (BD Biosciences) in 0.02 N acetic acid/PBS 1 .
2.2.2. Mesenchymal stem cells (MSC)
Bone marrow aspirates were obtained from patients during
orthopedic surgical procedures after exposure of the iliac
crest in the orthopedic department of Nantes University Hospital
(Dr. J. Delécrin). Normal human MSC were then puriﬁed by
centrifugation over Ficoll gradient (Sigma), 500,000 cells being
seeded and cultivated in DMEM medium supplemented with 10%
FBS. Adherent cells where then selected and cultivated with the
same medium supplemented with bFGF (1 ng/mL, R&D systems).
These cells are CD105+, CD90+, CD45− and CD90−.
2.2.3. Cell proliferation and viability
Subconﬂuent cultures of Ewing's sarcoma cells in 96-well
plates were treated for 72 h with increasing concentration (50,
100 and 200 ng/mL−1) of hOPG (R&D systems). Cell viability was
determined using the sodium 3′[1-(phenylaminocarbonyl)-3,4-
tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate
(XTT) cell proliferation reagent assay kit (Roche). Cell viability was
also assessed by trypan blue exclusion. The percentage of cells that
exhibit intra-cytoplasmic trypan blue staining was determined
using a Malassez counting chamber.
G. Picarda et al. / Journal of Bone Oncology 2 (2013) 95–10442.2.4. RANKL protein detection in Ewing's sarcoma
cell lysates by western-blot
Total protein extracts in Laemmli buffer (62.5 mM Tris–HCl, pH 6.8,
2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.001% bromophenol
blue) were separated by SDS-polyacrylamide gel electrophoresis, and
transferred to Immobilon-P membranes (Millipore). Membranes were
immunoblotted with anti-human RANKL (1/200, Santa Cruz), or anti-
β-actin (1/100, Sigma) antibodies. In both cases, secondary anti-rabbit
antibody was used at 1/10,000 (Santa Cruz). Antibody binding was
visualized with the enhanced chemiluminescence system (SuperSignal
West Pico Chemiluminescent Substrate, ThermoSientiﬁc). For quanti-
ﬁcation, luminescence was detected with a Charge Couple Device
(CCD) camera and analyzed using the GeneTools program (Syngene).2.2.5. RANKL and TRAIL mRNA expression in ES cell lines by real time
polymerase chain reaction
Total RNA was extracted using NucleoSpinsRNAII (Macherey
Nagel) and used for ﬁrst strand cDNA synthesis using ThermoScriptCT
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Fig. 1. Validation of the presence of RANKL in the Ewing's sarcoma tumor microenvironm
in 10 ES cell lines and compared to MSCs (see Section 2). (B) Basal RANKL protein expres
MSCs. (C) RANKL is detectable by immuno-ﬂuorescence in tumors induced in mice by in
was evidenced in the biopsies of Ewing's sarcoma patient ♯2 (with relapsed aggressive
(original magniﬁcation: 20 ).RT-PCR System (Invitrogen). Real-time PCR was performed with a
Chromo4 instrument (Biorad) using SYBR Green Supermix reagents
(Biorad).3. Results
3.1. RANKL is expressed by ES cells
The expression of RANKL was investigated at the mRNA and
protein levels using respectively real time PCR and western-blot
(and BioPlex) in the lysates of 10 human ES cell lines. RANKL
mRNA expression was also compared to MSCs. Results presented
in Fig. 1A showed that all Ewing's sarcoma cell lines studied
express RANKL mRNA but at variable levels depending on the cell
lines; RANKL seems to be more expressed in the SK-N-MC cell line,
then SK-ES-1, EW24 and A-673, while some cell lines showed
weak expression: TC-32, TC-71 or STA-ET-1. In comparison, MSC
do not express RANKL. These results were partly conﬁrmed at thehRANKL
Neg Ctrl RANKL
Patient 2
RANKL
-actinβ
ent. (A) The production of RANKL was analyzed at the mRNA level by real time PCR
sion is revealed by western-blot analysis in 5 ES cell lines and compared to human
jection of 2106 TC-71 ES cells (magniﬁcation 400 ); (D) the presence of RANKL
tumor) while biopsy from patient 1 (good responder to chemotherapy) is negative
G. Picarda et al. / Journal of Bone Oncology 2 (2013) 95–104 5protein level by western-blot analysis: TC-71, EW24, RDES and SK-
N-MC cell lines express RANKL, while TC-32 and MSC do not,
conﬁrming the results obtained at the mRNA level (Fig. 1B).
3.2. RANKL Is expressed in the ES tumor microenvironment
The expression of RANKL was then assessed in situ in tumor
samples taken from A-673 human Ewing's sarcoma models
(Fig. 1C). The immune staining was performed on 40-mm tumor
sections by immuno-histoﬂuorescence with antibodies targeting
the human form of the cytokine (see Section 2). The staining
protocol was designed to avoid cross reactions with the murine
form of RANKL, by saturating the murine sites using goat anti-
mouse Fab. A homogeneous expression of human RANKL was
observed in sections of A-673 tumors as shown in Fig. 1C, similar
results being obtained in another Ewing's Sarcoma model, in TC-
71tumor sections (data not shown).
The human origin of RANKL production was conﬁrmed in these
models by ELISA test comparing the staining with antibodies
speciﬁc of human or murine species. The human origin of RANKL
was evidenced both at the systemic level in the serum (1.2 versus
0.05 ng/mL, po0.001 respectively) or in the muscle (1.4 versus
0.1 ng/mL, po0.001), but more importantly at the tumor level (4.4
versus 0.2 ng/mL, po0.001). Results presented in Table 1 clearly
showed that RANKL detected in xenograft model of ES bearing
mice is from human origin both at the local and systemic levels,
with a more elevated amount found in the tumor itself.
3.3. RANKL is expressed in human biopsies
of Ewing's sarcoma patients.
Immuno-histochemistry analysis of two Ewing's sarcoma
patient biopsies show one positive and one negative staining for
RANKL, depending on the clinical aggressiveness of the tumorTable 1
Origin of RANKL present in the tumor microenvironment. Tumor and muscle lysats,
and serums of mice bearing Ewing's sarcoma were analyzed for the production of
human and mouse RANKL using species-speciﬁc ELISA detection Kits. Results are
expressed as ng/mL for serum detection and ng/mg of protein for detection on
muscle or tumor lysat.
Serum (ng/mL) Tumor (ng/mg) Muscle (ng/mg)
mRANKL 0.05 0.2 0.1
hRANKL 1.2nnn 4.4nnn 1.4nnn
nnn po0.001.
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Fig. 2. In vivo validation of OPG transgene expression in mice. (A) hOPG transgene expres
ﬁrst DNA/Lutrol administration. (B) hOPG transgene expression was assessed at the pro(the RANKL-positive tumor corresponds to the more aggressive
one which relapsed) (Fig. 1D). The positive staining was mostly
evidenced around necrosis areas observed in the tumor. However,
the cells producing RANKL seem to be the inﬂammatory cells or cells
from the immune system rather than the tumor cells themselves.
3.4. Vaidation of hOPG transgene expression in mice
Orthotopic human ES models were induced in immuno-
deﬁcient mice as described in Section 2. The mice were treated
with OPG by the injection of the F68/DNA complexes into the tibial
anterior muscles in mice. hOPG transgene overexpression of was
then validated by ELISA at both systemic (serum) and local (tumor)
levels in mice treated with hOPG compared to mice receiving the
mock pcDNA3.1 plasmid. Seven days after the ﬁrst injection of the
F68/DNA complex, the production of hOPG varied from 13.9 to
54.9 ng/mL in the serum of OPG-treated mice with a mean
production of 29.2716 ng/mL, signiﬁcantly higher than in the
pcDNA3.1 group where no hOPG expression could be detected
(po0.001, Fig. 2A). At the time of sacriﬁce, the hOPG concentra-
tion was also measured in the tumors. It reached a mean value of
17.8720.4 ng/mg in the hOPG treated group versus 2.971.7 ng/
mg in the pcDNA3.1 treated group (po0.001, Fig. 2B). The low
level of hOPG detected in the tumors of pcDNA3.1-treated mice
results probably from basal OPG production by the tumor cells
themselves. No correlation could be established between the
variability of OPG concentration and its therapeutic efﬁcacy.
3.5. hOPG decreases ES tumor progression in vivo
A preventive protocol of non-viral gene transfer using the
synthetic copolymer vector F68 from the Lutrol family was
designed to determine the potential protective effect of hOPG1-
194 on TC-71 ES tumor progression (n¼6). The results obtained in
the transplanted TC-71 model are representative of 4 other experi-
ments performed in the Ewing's sarcoma TC-71 and A-673 models
induced either by transplantation, or by intramuscular or intra-
osseous injection of 2 millions corresponding cells. A decrease of
the tumor incidence and a diminution of the tumor volume were
observed in the group of OPG-treated mice whatever the model
studied. For example at day 38 post-tumor cell injection, the mean
tumor volume is diminished in hOPG-treated mice 1647.871122
mm3 as compared to pcDNA3.1 control mice 2658.9.571090.6
mm3 (Fig. 3A). Despite a clear tendency in all experiments, these
results are statistically non-signiﬁcant. However, they show that
hOPG expression diminished the tumor incidence and progressionpcDNA3.1 hOPG
sionwas assessed at the protein level by ELISA in the serum of mice, 7 days after the
tein level by ELISA in tumor fragments at the time of sacriﬁce.
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Fig. 3. OPG decreases tumor development and increases animal survival in EWS tumor models in mice. Tumors were induced on Nude mice by transplantation of a fragment
of TC-71 tumor in close contact with the tibia as described in Section 2. Groups of 6 mice were assigned as pcDNA3.1 (empty pcDNA3.1 plasmid/F68 reagent) and hOPG
(pcDNA3.1.3-hOPG1-194/F68 reagent). The F68/DNA formulations were administered through intrasmuscular injection into the 2 tibial anterior muscles weekly, beginning
one week before tumor transplantation. (A) Mean tumor volume per group. (B) Overall survival for the 2 groups over a 42 days period. (C) Tumor volume evolution of
individual mice.
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group: 50% survival 43 days post-tumor implantation versus 16.3%
in pcDNA3.1 (Fig. 3B). Moreover, when considering each animal
individually 38 days after tumor transplantation, 5/6 mice had
developed a primary tumor of at least 1000 mm3 in the pcDNA3.1
group (Fig. 3C) versus only 2/6 in the hOPG-treated group (Fig. 3D).3.6. OPG decreases tumor associated bone remodeling
Microscanner analysis previously revealed high levels of osteo-
lytic lesions in the TC-71 ES model that was used in this study.
Radiographs of the A-673 implanted mouse tibiae presented in
Fig. 4A revealed a high bone remodeling, resulting in cortical
destruction and intensive interactions between altered bone tissue
and tumor cells, as compared with control mice (without tumor).
Bone lesions appear to be slightly inhibited in mice treated with
hOPG compared with mice treated with pcDNA3.1 (Fig. 4A). These
results were conﬁrmed and quantiﬁed by bone micro-architecture
analysis, showing an intense bone remodeling in the pcDNA3.1
group while micro-architecture is preserved in hOPG treated
animals (Fig. 4B). The speciﬁc bone volume of the trabeculae
(BV/TV) was increased in hOPG treated mice as compared with the
pcDNA3.1 group (respectively 43.575.4% versus 4074%, Fig. 4B).
Overall, these results showed a slight anti-bone resorption effect of
hOPG delivered by gene transfer using synthetic vectors in a
preventive protocol developed in a mouse model of ES.3.7. Recombinant soluble hOPG has no effect on ES cell
proliferation in vitro
To determine whether the inhibitory effect of OPG observed
in vivo could be due to direct effect on ES cell proliferation, TC-71
and A673 cells were treated during 72 h with increasing concen-
tration of soluble recombinant hOPG (0–200 ng/mL). In both cell
lines, no effect of hOPG on cell proliferation has been observed
(Fig. 5A).3.8. TRAIL is present in Ewing's sarcoma environment
In order to determine whether OPG inhibitory effects on RANKL
activity could be partially modulated by TRAIL, another member of
the TNF superfamily, we searched for TRAIL expression in the
Ewing's sarcoma microenvironment. To this aim, we ﬁrst analyze
by ELISA test the capacity of 8 ES tumors induced by injection of
2 millions corresponding ES cells to produce TRAIL (Fig. 5B).
Results clearly show that TRAIL can be detected in all the ES
tumors studied, values varying from 2.2 to 10.3 pg/mg proteins in
the cell lysate. As the ELISA test is human speciﬁc we can conclude
that TRAIL is produce by the tumor itself. To determine whether
TRAIL was produced directly by ES cells, its expression at the
transcript level was analyzed by RT-qPCR in 10 ES cell lines and
compared to normal human MSCs (Fig. 5C). The results showed
that except for two cell lines (EW7 and SK-N-MC), ES cells do not
express TRAIL.
In addition, TRAIL was detected by immuno-histochemistry in
two biopsies of Ewing's sarcoma patients, but its expression is
mainly associated with immune cells (Fig. 5D). This result suggests
that OPG given as therapeutic molecule could bind in situ to both
RANKL and TRAIL, and that TRAIL may interfere with OPG
inhibitory effect on RANKL mediated pro-bone resorption activity
in Ewing's sarcoma.4. Discussion
Therapeutic interest has recently increased on bone tumor
microenvironment as a new promising target for primary bone
diseases. Even if tumor cells are still the ﬁrst targets in cancer
therapy, an increased number of data suggest that tumor cell
proliferation in bone is highly dependent upon host cells from the
bone microenvironment. Indeed, as evidenced for bone metas-
tases, a vicious cycle between osteoclasts, bone stromal cells/
osteoblasts and cancer cells have been hypothesized during the
progression of primary bone tumors [11]. Tumor cells produce
osteoclast activating factors such as Interleukin-6, TNF-α or PTH-rP
pcDNA3.1 hOPGCT
pcDNA3.1 pcDNA3.3-hOPG
CT 
Without
tumor
BV/TV (%) 41.1 43.3 35.6 43.8 48.8 37.9
Fig. 4. Effect of OPG gene transfer on bone lesions associated with EWS progression in mice. (A) Tumor-associated osteolysis was analyzed by microCT at day 42 on
3 representative pcDNA3.1 mice and hOPG mice. The relative bone volume (BV/TV) is expressed as percent in each case. (B) Tumor-associated osteolysis analyzed by
radiography at day 42 on pcDNA3.1 mice and hOPG mice.
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production of RANKL. When they resorb bone, osteoclasts enable
the release of growth factors stored in the bone matrix (TGF-β,
IGF-1, PDGF, etc.) that in turn activate tumor cell proliferation [11].
Accordingly, inhibition of osteoclast activity represents a promis-
ing approach to block the vicious cycle, inhibiting indirectly local
cancer growth.
By inhibiting osteoclast activity, one possible option relies to
bisphosphonates, the synthetic analogs of pyrophosphate that
induce osteoclast apoptosis, decrease osteoclast activation and
function by inhibition of the mevalonate pathway [32]. Such
therapeutic tools have been studied in primary bone tumor
models [33,34] and are even used in the French clinical trial
OS2006 for pediatric and adult osteosarcoma patients. However,
these molecules exhibit secondary events especially renal toxicity
and osteonecrosis of the jaw, and may interfere with bone growth
when administered to young patients [35].
Therefore, another promising way to block osteoclast activation
is to target RANKL, the pivotal cytokine that mediate osteoclast
differentiation and activation [36]. Beyond physiological condi-
tions, increased expression of RANKL has been observed in
osteolytic malignancies, such as breast cancer and multiple mye-
loma [37–39]. A previous study demonstrated that the RANKL/OPG
ratio was signiﬁcantly increased in patients suffering from severe
osteolysis associated with tumor or not [19]. Therefore, therapeu-
tic strategies that used its decoy receptor OPG have emerged in
osteolytic bone tumor pathologies. As an example, OPG was shown
to inhibit cancer cell migration and bone metastasis through
inhibition of the RANKL-induced effects in RANK-expressing cells
from tumor origin [40]. OPG was also shown to inhibit tumor-
induced osteoclastogenesis and bone tumor growth in osteope-
trotic mice [41], to reduce bone cancer pain by the blockade of theongoing osteoclast activity [42], to decrease the number and area
of radiographically evident lytic bone lesions in a model of mouse
colon adenocarcinoma [21], to exhibit beneﬁcial effects in experi-
mental models of myeloma [20,43] and to inhibit osteolytic lesions
associated with prostate cancer [44].
In the present study, mice developing Ewing's sarcoma models
were treated by OPG administered by non-viral gene therapy. In a
ﬁrst step, we conﬁrmed that RANKL was indeed a good therapeu-
tic target in ES, by analyzing its expression both in patients and
also in the ES models used in the present study. RANKL expression
was indeed found in ES microenvironment in both cases, conﬁrm-
ing the results previously published by Taylor et al. in patient
biopsies [10]. Moreover, we demonstrate in the present study that
ES cells are directly producing RANKL. The availability of a
xenograft model of ES enabled us to discriminate from human or
murine origin of RANKL production. The antibodies used were
speciﬁc for each species and results clearly showed that the
increased RANKL production in ES tumor model was due to direct
synthesis by tumor cells. However, one interesting data is that
some ES cell lines (such as TC-71) which express low levels of
RANKL in vitro (Fig. 1A and B), show an elevated RANKL production
when injected in the mouse and developing a tumor (Fig. 1C).
Therefore, it suggests that during tumor development, the stroma
may inﬂuence tumor cells to produce RANKL. These results
constitute the rationale for the therapeutic use of OPG in ES.
A previous study from our group demonstrated that the
truncated form of OPG (1-194) has greater activity than the
complete form, given that proteoglycans present in the bone
tumor microenvironment may bind to full length OPG, thereby
limiting its bioavailability and bioactivity [31]. Therefore the
truncated form of OPG was used in the present study. The
transgene overexpression was conﬁrmed both at the systemic
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Fig. 5. Hypothesis on the OPG mechanisms of action in Ewing's sarcoma by binding TRAIL. (A) ES cells were cultured for 48 h in the presence of OPG. OPG has no direct effect
on ES cell proliferation in vitro. (B) TRAIL is expressed in ES tumor models. Assays were realized on protein lysats obtained from fragments of tumors induced by
intramuscular injection of human Ewing's sarcoma A-673 cells in nude mice, and normalized to respective protein levels (N¼number of tumor samples analyzed). (C) The
production of TRAIL was analyzed at the mRNA level by real time PCR in 10 ES cell lines and compared to human MSCs. (D) Two Ewing's sarcoma biopsies were analyzed for
TRAIL immuno-staining (see Section 2) (original magniﬁcation 20 ).
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OPG biological activity at the bone level, by prevention of
osteolytic lesions and preservation of cortical bone structure at
the tumor-bone interface. In addition, inhibition of tumor progres-
sion had been observed in all the series studied, both in models
induced by transplantation of tumor fragments or by tumor cell
injection. In all cases, the inhibition of the mean tumor volume
was not signiﬁcant (between 20% and 30% inhibition), probably
due to the heterogeneity of the model but when considering each
animal taken individually, there is a clear tendency to inhibition by
OPG treatment either on incidence or progression levels. Because
OPG has no direct effect on ES cell proliferation, OPG induced
diminution of tumor growth could be explained by an indirect
inhibitory effect on RANKL mediated bone resorption.
Several hypotheses can be proposed to explain why OPG has
only weak effect on ES progression.First, OPG is also able to bind another member of the TNF
family, the TNF Related Apoptosis Inducing Ligand (TRAIL,
TNFSF10)[45]. Several in vitro studies have even suggested that
OPG could represent a protumoral factor for cancer cells, by
inhibiting the pro-apoptosis activity of TRAIL [24–26]. This is
why we searched for TRAIL expression and production in the ES
microenvironment. We demonstrated that TRAIL is indeed
detected in xenograft ES tumors induced by injection of corre-
sponding human cells, but the ES cells themselves do not express
TRAIL as evidenced in 8 ES cell lines out of 10. TRAIL protein level
was also analyzed by immuno-histochemistry in human ES biop-
sies. Results showed that this cytokine is indeed present in the ES
microenvironment, but mainly produced by immune cells rather
than Es tumor cells. Therefore, TRAIL present in the microenviron-
ment could interfere with OPG to modulate OPG inhibitory effect
on RANKL activity [46]. In the same time, OPG expression was also
G. Picarda et al. / Journal of Bone Oncology 2 (2013) 95–104 9studied, both in the ES cell lines and in human ES biopsies. We
showed that ES cell lines do not express OPG at all, this result
being contradictory with those of Taylor et al. [10]. No OPG
expression could be also observed in patient biopsies.
Therefore, another way to block RANKL activity should be
proposed such as RANK-Fc or the humanized antibody anti-
RANKL Denosumab [47]. However, because this fully humanized
antibody cannot be used in preclinical studies in mice, we decided
to test the soluble receptor OPG. Denosumab is able to speciﬁcally
bind to RANKL blocking its activity, without any interference with
other members of the TNF superfamily such as TRAIL or FasL [48].
At the clinical level, the use of Denosumab is already proposed for
patients with malignancy associated osteolysis [49]. We could
therefore propose to combine Denosumab with chemotherapy in
the case of primary bone tumors, including Ewing's sarcoma.
Another hypothesis is that osteoclast activation is not only
driven by RANKL, but also by other cytokines such as TNF-α or M-
CSF (Macrophage-Colony Stimulating Factor). Indeed, previous
data reported that macrophages present in the ES tumor stroma
microenvironment could differentiate into osteoclasts in the pre-
sence of M-CSF and TNF-α [50]. In complement, the presence of
both cytokines in the microenvironment of ES xenograft models
was evidenced by immuno-ﬂuorescence and ELISA (not shown).
Therefore, a combined treatment could be proposed, associating
an anti-RANKL strategy with anti-TNF and anti-M-CSF ones.5. Conclusions
This study demonstrated that RANKL represents a good ther-
apeutic target for ES patients, but OPG cannot be used per se
because of its potential binding to TRAIL that may modulate its
inhibitory activity towards RANKL. The potential involvement of
two other cytokines that mediate osteoclast formation, i.e. TNF-α
and M-CSF should be extensively studied as well in the Ewing
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